RETRACTED ARTICLE: Combined treatment of glibenclamide and CoCl2 decreases MMP9 expression and inhibits growth in highly metastatic breast cancer

Abstract Background To observe the influence of combination treatment with glibenclamide and CoCl2 on the growth and invasiveness of TA2 breast cancer, and to detect the protein and mRNA expression of MMP9. Methods 50 adult female TA2 mice were randomly divided into 5 groups including DMSO control,...

Full description

Saved in:
Bibliographic Details
Main Authors: Zhe Rong, Li Li, Fei Fei, Lailong Luo, Yang Qu
Format: Article
Language:English
Published: BMC 2013-05-01
Series:Journal of Experimental & Clinical Cancer Research
Subjects:
Online Access:https://doi.org/10.1186/1756-9966-32-32
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1823861450115907584
author Zhe Rong
Li Li
Fei Fei
Lailong Luo
Yang Qu
author_facet Zhe Rong
Li Li
Fei Fei
Lailong Luo
Yang Qu
author_sort Zhe Rong
collection DOAJ
description Abstract Background To observe the influence of combination treatment with glibenclamide and CoCl2 on the growth and invasiveness of TA2 breast cancer, and to detect the protein and mRNA expression of MMP9. Methods 50 adult female TA2 mice were randomly divided into 5 groups including DMSO control, CoCl2, glibenclamide, CoCl2 + glibenclamide and paclitaxel. All of these mice were inoculated with TA2 spontaneous breast cancer cells in the left groin. Nine days after inoculation the tumor could be palpated. Different treatments for each group were then subcutaneously administered near the tumors on the 9th and 14th days after injection. Tumor size was measured to determine the growth curve. All mice were sacrificed on the 18th day after initial inoculation and tumor tissues were collected. Some fresh tissues without necrosis were stored at −80°C for mRNA detection and the other tumor tissue was fixed with 10% formalin for H&E and immunohistochemical staining. Results The growth rate of tumor cells in the CoCl2 + glibenclamide group was lower than that seen in the other groups. On the 14th day, the average volume of tumor in the CoCl2 + glibenclamide group was the lowest and the difference has statistical significance (P < 0.05), while the differences among the CoCl2, glibenclamide and paclitaxel had no statistical significance. The mean percentage of cells expressing MMP9 and PCNA was the lowest in the CoCl2 + glibenclamide group (P < 0.05). MMP9 mRNA expression paralleled MMP9 protein expression in these groups (P < 0.05). Conclusions Combined treatment with glibenclamide and CoCl2 inhibits TA2 spontaneous breast cancer growth and invasiveness with effects similar to paclitaxel.
format Article
id doaj-art-20b2c7655e7048ffabb9b7cd7cf20938
institution Kabale University
issn 1756-9966
language English
publishDate 2013-05-01
publisher BMC
record_format Article
series Journal of Experimental & Clinical Cancer Research
spelling doaj-art-20b2c7655e7048ffabb9b7cd7cf209382025-02-09T12:59:48ZengBMCJournal of Experimental & Clinical Cancer Research1756-99662013-05-013211710.1186/1756-9966-32-32RETRACTED ARTICLE: Combined treatment of glibenclamide and CoCl2 decreases MMP9 expression and inhibits growth in highly metastatic breast cancerZhe Rong0Li Li1Fei Fei2Lailong Luo3Yang Qu4Department of Basic Medicine & Experimental Technology, Division of Clinical Medicine, Logistic University of Chinese People’s Armed Police ForceDepartment of Pathology, Anhui Medical UniversityDepartment of Pathology, Anhui Medical UniversityDepartment of Pathology, Anhui Medical UniversityDepartment of Neurosurgery, Logistic University Affiliated Hospital, Logistic University of Chinese People’s Armed Police ForceAbstract Background To observe the influence of combination treatment with glibenclamide and CoCl2 on the growth and invasiveness of TA2 breast cancer, and to detect the protein and mRNA expression of MMP9. Methods 50 adult female TA2 mice were randomly divided into 5 groups including DMSO control, CoCl2, glibenclamide, CoCl2 + glibenclamide and paclitaxel. All of these mice were inoculated with TA2 spontaneous breast cancer cells in the left groin. Nine days after inoculation the tumor could be palpated. Different treatments for each group were then subcutaneously administered near the tumors on the 9th and 14th days after injection. Tumor size was measured to determine the growth curve. All mice were sacrificed on the 18th day after initial inoculation and tumor tissues were collected. Some fresh tissues without necrosis were stored at −80°C for mRNA detection and the other tumor tissue was fixed with 10% formalin for H&E and immunohistochemical staining. Results The growth rate of tumor cells in the CoCl2 + glibenclamide group was lower than that seen in the other groups. On the 14th day, the average volume of tumor in the CoCl2 + glibenclamide group was the lowest and the difference has statistical significance (P < 0.05), while the differences among the CoCl2, glibenclamide and paclitaxel had no statistical significance. The mean percentage of cells expressing MMP9 and PCNA was the lowest in the CoCl2 + glibenclamide group (P < 0.05). MMP9 mRNA expression paralleled MMP9 protein expression in these groups (P < 0.05). Conclusions Combined treatment with glibenclamide and CoCl2 inhibits TA2 spontaneous breast cancer growth and invasiveness with effects similar to paclitaxel.https://doi.org/10.1186/1756-9966-32-32GlibenclamideCoCl2Tientsin Albino 2Breast cancerMatrix metalloproteinase
spellingShingle Zhe Rong
Li Li
Fei Fei
Lailong Luo
Yang Qu
RETRACTED ARTICLE: Combined treatment of glibenclamide and CoCl2 decreases MMP9 expression and inhibits growth in highly metastatic breast cancer
Journal of Experimental & Clinical Cancer Research
Glibenclamide
CoCl2
Tientsin Albino 2
Breast cancer
Matrix metalloproteinase
title RETRACTED ARTICLE: Combined treatment of glibenclamide and CoCl2 decreases MMP9 expression and inhibits growth in highly metastatic breast cancer
title_full RETRACTED ARTICLE: Combined treatment of glibenclamide and CoCl2 decreases MMP9 expression and inhibits growth in highly metastatic breast cancer
title_fullStr RETRACTED ARTICLE: Combined treatment of glibenclamide and CoCl2 decreases MMP9 expression and inhibits growth in highly metastatic breast cancer
title_full_unstemmed RETRACTED ARTICLE: Combined treatment of glibenclamide and CoCl2 decreases MMP9 expression and inhibits growth in highly metastatic breast cancer
title_short RETRACTED ARTICLE: Combined treatment of glibenclamide and CoCl2 decreases MMP9 expression and inhibits growth in highly metastatic breast cancer
title_sort retracted article combined treatment of glibenclamide and cocl2 decreases mmp9 expression and inhibits growth in highly metastatic breast cancer
topic Glibenclamide
CoCl2
Tientsin Albino 2
Breast cancer
Matrix metalloproteinase
url https://doi.org/10.1186/1756-9966-32-32
work_keys_str_mv AT zherong retractedarticlecombinedtreatmentofglibenclamideandcocl2decreasesmmp9expressionandinhibitsgrowthinhighlymetastaticbreastcancer
AT lili retractedarticlecombinedtreatmentofglibenclamideandcocl2decreasesmmp9expressionandinhibitsgrowthinhighlymetastaticbreastcancer
AT feifei retractedarticlecombinedtreatmentofglibenclamideandcocl2decreasesmmp9expressionandinhibitsgrowthinhighlymetastaticbreastcancer
AT lailongluo retractedarticlecombinedtreatmentofglibenclamideandcocl2decreasesmmp9expressionandinhibitsgrowthinhighlymetastaticbreastcancer
AT yangqu retractedarticlecombinedtreatmentofglibenclamideandcocl2decreasesmmp9expressionandinhibitsgrowthinhighlymetastaticbreastcancer